Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism
Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
Long non-coding RNA mediated drug resistance in breast cancer
Breast cancer is one of the most prevalent cancers in women and a leading cause of
mortality. As per the GLOBCAN report of 2021, breast cancer has surpassed lung cancer …
mortality. As per the GLOBCAN report of 2021, breast cancer has surpassed lung cancer …
[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel …
M Johnson, MC Garassino, T Mok, T Mitsudomi - Lung Cancer, 2022 - Elsevier
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
J Li, L Zhu, HF Kwok - Drug Resistance Updates, 2023 - Elsevier
Lung cancer continues to be a malignant tumor with high mortality. Two obstacles interfere
with curative therapy of lung cancer:(i) poor diagnosis at the early stages, as symptoms are …
with curative therapy of lung cancer:(i) poor diagnosis at the early stages, as symptoms are …
Phosphorylation-dependent regulation of WNT/beta-catenin signaling
K Shah, JU Kazi - Frontiers in Oncology, 2022 - frontiersin.org
WNT/β-catenin signaling is a highly complex pathway that plays diverse roles in various
cellular processes. While WNT ligands usually signal through their dedicated Frizzled …
cellular processes. While WNT ligands usually signal through their dedicated Frizzled …
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
Y Li, T Mao, J Wang, H Zheng, Z Hu, P Cao… - Cell Communication and …, 2023 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
Discovery of selective and potent macrocyclic CDK9 inhibitors for the treatment of osimertinib-resistant non-small-cell lung cancer
T Wu, B Yu, Y Xu, Z Du, Z Zhang, Y Wang… - Journal of Medicinal …, 2023 - ACS Publications
Effectiveness of epidermal growth factor receptor (EGFR) inhibitors, including Osimertinib,
for treating non-small-cell lung cancer (NSCLC) is limited due to the continuous emergence …
for treating non-small-cell lung cancer (NSCLC) is limited due to the continuous emergence …
Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has
significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant lung …
significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant lung …
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
S Chen, Y Zhao, S Liu, J Zhang, YG Assaraf… - Drug Resistance …, 2022 - Elsevier
Despite the rapid advancement in the introduction of new drugs for cancer therapy, the
frequent emergence of drug resistance leads to disease progression or tumor recurrence …
frequent emergence of drug resistance leads to disease progression or tumor recurrence …
Design, synthesis, analysis, evaluation of cytotoxicity against MCF-7 breast cancer cells, 3D QSAR studies and EGFR, HER2 inhibition studies on Novel Biginelli 1, 4 …
NL Naishima, S Faizan, RM Raju, ASVL Sruthi… - Journal of Molecular …, 2023 - Elsevier
Dihydropyrimidines are usually synthesized from Biginelli reaction which are well known for
their anti-cancer activity. A series of novel Biginelli-1, 4-dihydropyrimidines are rationally …
their anti-cancer activity. A series of novel Biginelli-1, 4-dihydropyrimidines are rationally …